A groundbreaking advancement in cancer treatment is set to transform the way advanced bowel cancer is managed, potentially saving thousands of patients from unnecessary side effects. Researchers from London’s Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have unveiled PhenMap, an innovative artificial intelligence tool designed to predict how individual patients will respond to the new NHS-approved drug, bevacizumab.
Understanding Bowel Cancer’s Challenges
Every year, nearly 10,000 individuals in the UK are diagnosed with advanced bowel cancer, a condition that poses a particularly stark risk to younger adults. This form of cancer ranks as the second leading cause of cancer-related deaths, trailing only lung cancer. While early detection can yield a remarkable five-year survival rate of up to 98%, the prognosis for advanced cases plummets to a mere 10%.
The introduction of bevacizumab, which received NHS approval in December, offers some hope. This drug operates by inhibiting the growth of tumours through the deprivation of essential proteins. However, its effectiveness is limited to a specific subset of patients, and it carries serious risks, including the potential for blood clots and gastrointestinal complications.
The Role of PhenMap
The PhenMap tool utilises advanced algorithms to consolidate extensive data regarding the genetic characteristics of tumours. By analysing this information, the researchers have been able to identify distinct patterns in how various patients respond to bevacizumab. Notably, they discovered a group of patients sharing a common gene mutation who exhibited high susceptibility to adverse reactions.
Professor Anguraj Sadanandam, an expert in stratification and precision medicine at the Institute of Cancer Research, emphasised the importance of such technology in refining treatment pathways. “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS,” Sadanandam stated.
He further highlighted the necessity of this innovation: “We know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily. Until now, we haven’t been able to identify these patients.”
Future Directions and Validation
While the results from the initial study of 117 European patients are promising, Sadanandam acknowledged the need for further validation through larger sample sizes. “Our research uses advanced AI methods to pull together large amounts of complex data, helping us to spot patterns that would otherwise be impossible for a human to see,” he explained.
The ultimate goal is to develop a clinically applicable test that could allow healthcare providers to offer personalised care tailored to the specific needs and genetic make-up of each patient, thereby maximising the likelihood of successful treatment outcomes.
Why it Matters
The implications of this research extend far beyond individual patient care; they signal a significant shift towards precision medicine in the treatment of cancer. With the ability to determine the efficacy of treatments based on genetic factors, PhenMap could revolutionise how healthcare systems allocate resources, ensuring that each patient receives the most appropriate and effective therapies available. This not only enhances patient safety but also optimises treatment costs, paving the way for a more efficient and humane approach to cancer care.
